However, about ∼20% of adenocarcinoma patients and the majority of squamous cell and non-small cell lung cancer patients will not benefit from the pafolacianine probe due to a lack of folate alpha receptors in the primary tumors. This evidence concerns the gene FOLR1 and adenocarcinoma.